Citation

Scharre DW, Chang SI. Alzheimer Dis. Assoc. Disord. 2002; 16(2): 128-130.

Affiliation

Division of Cognitive Neurology, Department of Neurology, The Ohio State University, Columbus, Ohio, USA.

Copyright

(Copyright © 2002, Lippincott Williams and Wilkins)

DOI

unavailable

PMID

12040309

Abstract

In a prospective, open-label, 12-week pilot study in outpatients with probable Alzheimer disease (AD) with psychosis or aggressive behaviors, we used the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog) and the Neuropsychiatric Inventory (NPI) to evaluate the cognitive and behavioral effects of quetiapine. After receiving doses ranging from 50 to 150 mg, patients given quetiapine showed a significant decrease of delusions, aggression, and overall behaviors based on NPI scores at 6 and 12 weeks. ADAS-cog scores did not show a significant change over 12 weeks. This study provides initial evidence that quetiapine does not significantly worsen cognition in AD outpatients.

Language: en